budesonide + zafirlukast

Budesonide + zafirlukast is a combination of two pharmaceutical agents used in the management of asthma. Budesonide is an inhaled corticosteroid that reduces inflammation in the airways, while zafirlukast is an oral leukotriene receptor antagonist that blocks leukotriene-mediated bronchoconstriction and inflammation. The combination aims to provide additive or synergistic effects for improved asthma control, particularly in patients who do not achieve adequate symptom relief with monotherapy. Budesonide acts by binding to glucocorticoid receptors and modulating gene expression to suppress pro-inflammatory cytokines, whereas zafirlukast selectively antagonizes cysteinyl leukotriene type 1 (CysLT1) receptors on airway smooth muscle and other cells involved in the asthmatic response[3][5][4].